Alnylam Pharmaceuticals (ALNY) News Today $246.27 -2.89 (-1.16%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Gateway Investment Advisers LLC Purchases 1,222 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Gateway Investment Advisers LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,383 shares of the biopharmaceutical company's stoJanuary 18 at 4:18 AM | marketbeat.comEmpirical Asset Management LLC Buys New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Empirical Asset Management LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 51,614 shares of the bioJanuary 17 at 7:34 AM | marketbeat.comFY2024 Earnings Estimate for ALNY Issued By Zacks ResearchAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities researchers at Zacks Research upped their FY2024 earnings estimates for shares of Alnylam Pharmaceuticals in a report issued on Tuesday, January 14th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutiJanuary 17 at 7:05 AM | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 6.7% - Here's What HappenedAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Down 6.7% - Here's WhyJanuary 16 at 10:44 PM | marketbeat.comAlnylam Pharma (ALNY) Gets a Buy from Raymond JamesJanuary 16 at 5:36 PM | markets.businessinsider.comCautious Hold on Alnylam Pharma Amid Uncertain Projections and Awaited Pipeline ProgressJanuary 16 at 5:36 PM | markets.businessinsider.comWhat is William Blair's Estimate for ALNY FY2024 Earnings?January 16 at 1:43 AM | americanbankingnews.comBurney Co. Increases Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Burney Co. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 22.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,738 shares of the biopharmaceutical company's stock after buying an additional 4,7January 15 at 9:55 AM | marketbeat.comWhat is William Blair's Forecast for ALNY FY2024 Earnings?Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities research analysts at William Blair raised their FY2024 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research note issued to investors on Sunday, January 12th. William Blair analyst M. Minter now expects thJanuary 15 at 6:42 AM | marketbeat.comPiper Sandler Reaffirms Their Buy Rating on X4 Pharmaceuticals (XFOR)January 14, 2025 | markets.businessinsider.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Shares Down 6.7% - What's Next?Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 6.7% - Here's What HappenedJanuary 14, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Given Buy Rating at HC WainwrightJanuary 14, 2025 | americanbankingnews.comHealthcare executives weigh policy unknowns at San Francisco gatheringJanuary 13, 2025 | ft.comBalanced Hold Rating on Alnylam Pharma Amid Promising Growth and UncertaintiesJanuary 13, 2025 | markets.businessinsider.comAlnylam shares jump on strong revenue forecast and profit outlookJanuary 13, 2025 | in.investing.comStrong Growth Prospects and Financial Performance Drive Buy Rating for Alnylam PharmaJanuary 13, 2025 | markets.businessinsider.comAlnylam Pharma’s Strong Revenue Performance and Growth Potential Justifies ‘Buy’ RatingJanuary 13, 2025 | markets.businessinsider.comAlnylam Shares Rise 8% On Preliminary Product Revenue GrowthJanuary 13, 2025 | marketwatch.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Trading 7.1% Higher - Should You Buy?Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading 7.1% Higher - Still a Buy?January 13, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)HC Wainwright reaffirmed a "buy" rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday.January 13, 2025 | marketbeat.comAlnylam Pharma: Strong Financial Performance and Promising Growth ProspectsJanuary 13, 2025 | markets.businessinsider.comAlnylam Pharma’s Strong Financial Performance and Growth Prospects Justify Buy RatingJanuary 13, 2025 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)Needham & Company LLC reissued a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday.January 13, 2025 | marketbeat.comAlnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline GoalsJanuary 12, 2025 | businesswire.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Cut to Hold at StockNews.comJanuary 12, 2025 | americanbankingnews.comStocks Generating Improved Relative Strength: Alnylam PharmaceuticalsJanuary 10, 2025 | msn.comStockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to HoldStockNews.com cut Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday.January 9, 2025 | marketbeat.comBiotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.January 9, 2025 | msn.comSanford C. Bernstein Lowers Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $310.00January 8, 2025 | americanbankingnews.comAlnylam price target lowered to $310 from $314 at BernsteinJanuary 7, 2025 | markets.businessinsider.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $310.00 at Sanford C. BernsteinSanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a report on Tuesday.January 7, 2025 | marketbeat.comAlnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025January 7, 2025 | seekingalpha.comAlnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025January 7, 2025 | seekingalpha.comAlnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | finance.yahoo.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-four brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and eiJanuary 5, 2025 | marketbeat.comEverence Capital Management Inc. Invests $593,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Everence Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,520 shares of the biopharmaceuticalJanuary 5, 2025 | marketbeat.comAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 25.2% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,608 shares of the biopharmaceutical company's stock after selling 3January 4, 2025 | marketbeat.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Friday.December 27, 2024 | marketbeat.comExploring High Growth Tech Stocks in the US December 2024December 26, 2024 | finance.yahoo.comNeedham Remains a Hold on Lexicon Pharmaceuticals (LXRX)December 23, 2024 | markets.businessinsider.comVertex Pharmaceuticals (VRTX) Receives a Buy from Bank of America SecuritiesDecember 23, 2024 | markets.businessinsider.comIs Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024?December 23, 2024 | msn.comGIVLAARI® (givosiran injection) Now Widely Reimbursed in Canada For the Treatment of Acute Hepatic Porphyria (AHP) in AdultsDecember 23, 2024 | finance.yahoo.comSanctuary Advisors LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)Sanctuary Advisors LLC raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 91.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,558 shares of the biopharmacDecember 21, 2024 | marketbeat.comIonis Pharmaceuticals Receives Buy Rating Following TRYNGOLZA FDA Approval and Strategic Market PositioningDecember 20, 2024 | markets.businessinsider.comHow Pharma Companies Can Balance Affordability With InnovationDecember 20, 2024 | msn.comBiotech CEO on RNAI and Medicine of the FutureDecember 20, 2024 | msn.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by StockNews.com to "Buy" RatingStockNews.com raised Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Wednesday.December 18, 2024 | marketbeat.comLeerink Partners Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)December 18, 2024 | markets.businessinsider.comCautious Optimism for Tenaya Therapeutics’ TN-201: Early Phase Study Shows Promising Efficacy and SafetyDecember 18, 2024 | markets.businessinsider.com Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNY Media Mentions By Week ALNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALNY News Sentiment▼0.690.57▲Average Medical News Sentiment ALNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALNY Articles This Week▼3211▲ALNY Articles Average Week Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Gilead Sciences News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Biogen News United Therapeutics News Neurocrine Biosciences News Incyte News BioMarin Pharmaceutical News Exact Sciences News Exelixis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALNY) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
